DWP16001与二甲双胍在健康受试者中的药代与药效相互作用研究
本研究在健康男性受试者中开展随机、开放、单次及多次给药、两序列交叉试验,评估DWP16001与二甲双胍联用的药代与药效变化。结果显示联用时DWP16001峰浓度和AUC升高,但二甲双胍药代及尿糖排泄无临床相关改变。结论认为两药可联用而无临床相关相互作用。
要点
- DWP16001联用二甲双胍后峰浓度GMR为1.22,超出标准生物等效界值。
- 二甲双胍稳态峰浓度及AUC的GMR分别为0.98和1.05,无临床相关改变。
- 联用与单用DWP16001的尿糖排泄量GMR为0.99,药效相当。
核心结论
- DWP16001与二甲双胍可联用,未观察到临床相关的药代或药效相互作用。
研究设计与样本
- 随机、开放、单次及多次给药、两序列交叉研究,在健康男性受试者中开展。
主要发现
- DWP+MET与DWP相比,峰浓度GMR为1.22(90%CI 1.13-1.31),AUC0-tlast GMR为1.09(90%CI 1.05-1.14)。
- DWP+MET与MET相比,稳态峰浓度GMR为0.98(90%CI 0.90-1.06),稳态AUCtau GMR为1.05(90%CI 0.98-1.13)。
- DWP+MET与DWP相比,0-144小时尿糖排泄量GMR为0.99(90%CI 0.94-1.05)。
关键数值与推荐
- 药代参数比较采用标准生物等效界值0.8-1.25。
临床怎么用
- 临床联用DWP16001与二甲双胍时,无需基于药代或药效相互作用调整剂量。
局限性
- 研究仅纳入健康男性受试者,未覆盖女性及2型糖尿病患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: DWP16001 is a novel sodium-glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes with selective and sustained sodium-glucose cotransporter 2 inhibition. We aimed to evaluate whether the coadministration of DWP16001 and metformin causes any changes in pharmacokinetics (PK) or pharmacodynamics (PD). METHODS: A randomized, open-label, single- and multiple-dose, 2-sequence, crossover study was conducted in healthy male subjects. Subjects received the following treatments: a single oral dose of DWP16001 (DWP) 2 mg, metformin immediate release 1000 mg (MET) twice daily for 7 days and a single oral dose of DWP and MET at steady-state for metformin (DWP+MET). Serial blood and interval urine were collected for PK and PD analyses. Safety and tolerability profiles were assessed throughout the study. RESULTS: DWP+MET displayed increased peak concentration and area under the concentration-time curve from time 0 to time of the last quantifiable concentration compared with DWP (per standard bioequivalence boundaries, 0.8-1.25); the geometric mean ratios (GMRs) and their 90% confidence intervals (CIs) were 1.22 (1.13-1.31) and 1.09 (1.05-1.14), respectively. DWP+MET and MET showed similar peak concentration and area under the concentration-time curve within a dosing interval at steady state for metformin; the GMRs and 90% CIs were 0.98 (0.90-1.06) and 1.05 (0.98-1.13), respectively. The amount of urinary glucose excretion from time 0 to 144 h was also comparable between DWP+MET and DWP (GMR and 90% CI; 0.99, 0.94-1.05). CONCLUSION: The results suggest that DWP16001 and metformin could be coadministered without clinically relevant PK and PD interactions.
引用
- Kim B, Huh KY, Hwang JG, et al. Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium-glucose cotransporter 2 inhibitor and metformin in healthy subjects. Br J Clin Pharmacol. 2022. PMID: 36422809. doi:10.1111/bcp.15613
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。